Arab Drug sees 161% YoY higher profits in H1 FY2024/25

Updated 2/2/2025 9:39:00 AM
Arab Drug sees 161% YoY higher profits in H1 FY2024/25

Arab Finance: Arab Drug Company (ADCI) posted net profits after tax of EGP 106 million in the first half (H1) of fiscal year (FY) 2024/2025, according to a bourse statement on February 2nd.

This is 161% year-on-year (YoY) higher than the recorded EGP 65.68 million in H1 FY2023/24.

Meanwhile, the company’s sales amounted to EGP 558.12 million during the period from July to December 2024, an annual hike of 135% from EGP 413.89 million.

Basic earnings per share (EPS) increased by 161% YoY to EGP 15.17 in H1 FY2024/25 from EGP 9.39.

In FY 2023/24, the EGX-listed firm logged net profits after tax worth EGP 102.82 million, up 24.2% YoY from EGP 82.77 million.

Arab Drug is an Egypt-based company that focuses on the manufacturing, packaging, and distribution of pharmaceutical products as well as chemical solutions for human and veterinary use.

Related News